NCT04534725View on ClinicalTrials.gov

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

PHASE3CompletedINTERVENTIONAL
Enrollment

441

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

November 28, 2022

Study Completion Date

April 19, 2023

Conditions
CancerCovid19Respiratory Viral Infection
Interventions
DRUG

Interferon alfa

intranasal spray

DRUG

Selinexor

oral tablet

DRUG

Lenzilumab

intravenous infusion

Trial Locations (5)

2145

Westmead Hospital, Westmead

3000

Peter MacCallum Cancer Centre, Melbourne

3052

Royal Melbourne Hospital, Melbourne

3065

St Vincent's Hospital, Fitzroy

3084

Austin Health, Melbourne

All Listed Sponsors
lead

Peter MacCallum Cancer Centre, Australia

OTHER

NCT04534725 - COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; | Biotech Hunter | Biotech Hunter